Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2021

View Archived Issues

CEPI and VBI Vaccines partner to develop eVLP vaccine candidates against COVID-19 variants

Venatorx selects VNRX-9945 as clinical candidate against HBV

Enrollment opens in phase III trial of [177Lu]PNT-2002 for metastatic CRPC

First clinical results reported for SeVRSV vaccine in healthy adults

Moderna begins dosing with modified COVID-19 vaccines in amended phase II study

Nouscom cleared in Spain to begin phase Ib study of personalized cancer immunotherapy NOUS-PEV

First patients enrolled in phase I study of PTP-001 as treatment of knee OA

Positive biomarker data from phase II study of EB-613 in postmenopausal osteoporosis

Renibus initiates phase II trial of RBT-1 for prevention of AKI

BeiGene discloses MAP4K1 inhibitors

Sichuan Haisco Pharmaceutical synthesizes influenza virus hemagglutinin inhibitors

Hinova Pharmaceuticals identifies new thyroid hormone receptor beta agonists

Genfleet Therapeutics presents GTPase KRAS mutant inhibitors

BoYuan RunSheng Pharma patents CAR T cells for cancer

Novel antibody cocktail prevents SARS-CoV-2 viral escape mutations

Direct bladder vaccination halts recurrent UTIs

Tilavonemab does not show evidence of efficacy in phase II study in progressive supranuclear palsy

Sanofi and Translate Bio begin phase I/II study of MRT-5500 mRNA COVID-19 vaccine candidate

Takeda compound targets O-GlcNAcase for neurodegenerative disorders

SymBio submits IND for phase II trial of intravenous brincidofovir for pediatric AdV infections

Brilacidin inhibits SARS-CoV-2 in vitro

European Commission grants conditional marketing authorization for J&J COVID-19 vaccine

VX-880 enters phase I/II trial for type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...